{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T03:23:33Z","timestamp":1785813813719,"version":"3.56.0"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T00:00:00Z","timestamp":1566172800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T00:00:00Z","timestamp":1566172800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ontario Drug Policy Research Network"},{"name":"Ontario Ministry of Research, Innovation, and Science Early Researcher Award"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Syst Rev"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13643-019-1126-1","type":"journal-article","created":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T11:02:53Z","timestamp":1566212573000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Antiviral treatment for treatment-na\u00efve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials"],"prefix":"10.1186","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4630-0052","authenticated-orcid":false,"given":"William W. L.","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros","family":"Pechivanoglou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna M.","family":"Bielecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Haines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aysegul","family":"Erman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arcturus","family":"Phoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Tadrous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Younis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noha Z.","family":"Rayad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Rac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry L. A.","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murray D.","family":"Krahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,19]]},"reference":[{"key":"1126_CR1","unstructured":"Organization WH. Global hepatitis report 2017: World Health Organization; 2017."},{"issue":"2","key":"1126_CR2","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"Liver EAFTSOT","year":"2017","unstructured":"Liver EAFTSOT. EASL 2017 Clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370\u201398.","journal-title":"J Hepatol"},{"key":"1126_CR3","doi-asserted-by":"publisher","first-page":"5C","DOI":"10.1155\/2007\/910831","volume":"21 Suppl C","author":"M Sherman","year":"2007","unstructured":"Sherman M, Shafran S, Burak K, Doucette K, Wong W, Girgrah N, et al. Management of chronic hepatitis B: consensus guidelines. Can J Gastroenterol. 2007;21 Suppl C:5C\u201324C.","journal-title":"Can J Gastroenterol"},{"issue":"5 Suppl","key":"1126_CR4","doi-asserted-by":"publisher","first-page":"S174","DOI":"10.1002\/hep.22900","volume":"49","author":"MG Ghany","year":"2009","unstructured":"Ghany MG, Doo EC. Antiviral Resistance and hepatitis B therapy. Hepatology (Baltimore, Md). 2009;49(5 Suppl):S174\u2013S84.","journal-title":"Hepatology (Baltimore, Md)."},{"key":"1126_CR5","unstructured":"Drugs@FDA: FDA Approved Drug Products: Tenofovir Alafenamide Fumarate [Available from: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=208464 . Accessed 1 July 2018."},{"key":"1126_CR6","unstructured":"Health Canada Drug Product Database [Available from: https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/drug-products\/drug-product-database.html . Accessed 1 July 2018."},{"issue":"1","key":"1126_CR7","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/jvh.12613","volume":"24","author":"Y Liu","year":"2017","unstructured":"Liu Y, Corsa A, Buti M, Cathcart A, Flaherty J, Miller M, et al. No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg\u2212 patients with chronic hepatitis B after 8 years of treatment. Journal of viral hepatitis. 2017;24(1):68\u201374.","journal-title":"Journal of viral hepatitis."},{"issue":"10","key":"1126_CR8","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1155\/2011\/864046","volume":"25","author":"M Sherman","year":"2011","unstructured":"Sherman M, Lee SS. Canadian patients with chronic hepatitis B cannot access appropriate drug treatments: a call for change. Can J Gastroenterol. 2011;25(10):538\u201341.","journal-title":"Can J Gastroenterol."},{"issue":"4","key":"1126_CR9","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1053\/j.gastro.2010.06.042","volume":"139","author":"G Woo","year":"2010","unstructured":"Woo G, Tomlinson G, Nishikawa Y, Kowgier M, Sherman M, Wong DKH, et al. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology. 2010;139(4):1218\u201329.","journal-title":"Gastroenterology."},{"issue":"4","key":"1126_CR10","first-page":"380","volume":"27","author":"S Ismail","year":"2014","unstructured":"Ismail S, Hafez HA, Darweesh SK, Kamal KH, Esmat G. Virologic response and breakthrough in chronic hepatitis B Egyptian patients receiving lamivudine therapy. Ann Gastroenterol. 2014;27(4):380\u20136.","journal-title":"Ann Gastroenterol"},{"issue":"3","key":"1126_CR11","doi-asserted-by":"publisher","first-page":"e0174046","DOI":"10.1371\/journal.pone.0174046","volume":"12","author":"Y-J Huang","year":"2017","unstructured":"Huang Y-J, Chang C-S, Peng Y-C, Yeh H-Z, Yang S-S. On-treatment HBV DNA dynamics predict virological breakthrough in entecavir-treated HBeAg-positive chronic hepatitis B. PLoS One. 2017;12(3):e0174046.","journal-title":"PLoS One."},{"issue":"2","key":"1126_CR12","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s40121-015-0070-1","volume":"4","author":"A Ustianowski","year":"2015","unstructured":"Ustianowski A, Arends JE. Tenofovir: What we have learnt after 7.5 Million person-years of use. infectious diseases and therapy. 2015;4(2):145\u201357.","journal-title":"infectious diseases and therapy."},{"key":"1126_CR13","volume-title":"FINAL CENSORED REPORT: Treatment for chronic hepatitis B","author":"WW Wong","year":"2015","unstructured":"Wong WW, Pechlivanoglou P, Erman A, Saeed Y, Younis M, Rayad NZ, et al. FINAL CENSORED REPORT: Treatment for chronic hepatitis B. 2015."},{"key":"1126_CR14","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.","journal-title":"BMJ."},{"key":"1126_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","volume":"4","author":"D Moher","year":"2015","unstructured":"Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.","journal-title":"Syst Rev."},{"key":"1126_CR16","unstructured":"Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0 The Cochrane Collaboration; [updated March 2011]. Available from: http:\/\/handbook-5-1.cochrane.org\/ ."},{"issue":"oct18 2","key":"1126_CR17","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"J. P. T. Higgins","year":"2011","unstructured":"Higgins JPT, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343.","journal-title":"BMJ"},{"key":"1126_CR18","volume-title":"JAGS: a program for analysis of Bayesian graphical models using Gibbs sampling","author":"M Plummer","year":"2003","unstructured":"Plummer M. JAGS: a program for analysis of Bayesian graphical models using Gibbs sampling. Vienna: Proceedings of the 3rd international workshop on distributed statistical computing; 2003."},{"issue":"4","key":"1126_CR19","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/jrsm.1054","volume":"3","author":"G van Valkenhoef","year":"2012","unstructured":"van Valkenhoef G, Lu G, de Brock B, Hillege H, Ades AE, Welton NJ. Automating network meta-analysis. Res Synth Methods. 2012;3(4):285\u201399.","journal-title":"Res Synth Methods."},{"issue":"4","key":"1126_CR20","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1080\/10618600.1998.10474787","volume":"7","author":"SP Brooks","year":"1998","unstructured":"Brooks SP, Gelman A. General methods for monitoring convergence of iterative simulations. Journal of computational and graphical statistics. 1998;7(4):434\u201355.","journal-title":"Journal of computational and graphical statistics."},{"issue":"7-8","key":"1126_CR21","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/sim.3767","volume":"29","author":"S Dias","year":"2010","unstructured":"Dias S, Welton N, Caldwell D, Ades A. Checking consistency in mixed treatment comparison meta analysis. Statistics in medicine. 2010;29(7-8):932\u201344.","journal-title":"Statistics in medicine."},{"issue":"5","key":"1126_CR22","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1002\/hep.27586","volume":"61","author":"WP Brouwer","year":"2015","unstructured":"Brouwer WP, Xie Q, Sonneveld MJ, Zhang N, Zhang Q, Tabak F, et al. Adding pegylated interferon to entecavir for hepatitis B e antigen\u2013positive chronic hepatitis B: A multicenter randomized trial (ARES study). Hepatology. 2015;61(5):1512\u201322.","journal-title":"Hepatology."},{"key":"1126_CR23","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1111\/1751-2980.12065","volume":"14","author":"ZH Cao","year":"2013","unstructured":"Cao ZH, Ma LN, Zhang HW, Liu YL, Chen XY. Extended treatment with peginterferon alpha-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion. Journal of Digestive Diseases. 2013;14:446\u201350.","journal-title":"Journal of Digestive Diseases."},{"issue":"11","key":"1126_CR24","doi-asserted-by":"publisher","first-page":"745","DOI":"10.7326\/0003-4819-147-11-200712040-00183","volume":"147","author":"HL Chan","year":"2007","unstructured":"Chan HL, Heathcote EJ, Marcellin P, Lai CL, Cho M, Moon YM, et al. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med. 2007;147(11):745\u201354.","journal-title":"Ann Intern Med."},{"issue":"3","key":"1126_CR25","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S2468-1253(16)30024-3","volume":"1","author":"HL Chan","year":"2016","unstructured":"Chan HL, Fung S, Seto WK, Chuang W-L, Chen C-Y, Kim HJ, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. The Lancet Gastroenterology & Hepatology. 2016;1(3):185\u201395.","journal-title":"The Lancet Gastroenterology & Hepatology."},{"issue":"10","key":"1126_CR26","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJMoa051285","volume":"354","author":"TT Chang","year":"2006","unstructured":"Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354(10):1001\u201310.","journal-title":"N Engl J Med."},{"issue":"17","key":"1126_CR27","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1056\/NEJM199910213411702","volume":"341","author":"JL Dienstag","year":"1999","unstructured":"Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med. 1999;341(17):1256\u201363.","journal-title":"N Engl J Med."},{"key":"1126_CR28","doi-asserted-by":"crossref","unstructured":"He Z, Wang J, Liu K, Huang H, Du Y, Lin Z, et al. Randomized trial of lamivudine, adefovir, and the combination in HBeAg-positive chronic hepatitis B. Clinics and research in hepatology and gastroenterology [Internet]. 2012; 36(6):[592-597 pp.]. Available from: http:\/\/onlinelibrary.wiley.com\/o\/cochrane\/clcentral\/articles\/488\/CN-00859488\/frame.html .","DOI":"10.1016\/j.clinre.2012.05.012"},{"issue":"9454","key":"1126_CR29","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0140-6736(05)17701-0","volume":"365","author":"HL Janssen","year":"2005","unstructured":"Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet. 2005;365(9454):123\u20139.","journal-title":"Lancet."},{"key":"1126_CR30","doi-asserted-by":"crossref","unstructured":"Koike K, Suyama K, Ito H, Itoh H, Sugiura W. Randomized prospective study showing the non-inferiority of tenofovir to entecavir in treatment-na\u00efve chronic hepatitis B patients. Hepatology Research. 2017.","DOI":"10.1111\/hepr.12902"},{"issue":"2","key":"1126_CR31","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1056\/NEJM199807093390201","volume":"339","author":"CL Lai","year":"1998","unstructured":"Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med. 1998;339(2):61\u20138.","journal-title":"N Engl J Med."},{"issue":"2","key":"1126_CR32","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.gastro.2005.05.053","volume":"129","author":"CL Lai","year":"2005","unstructured":"Lai CL, Leung N, Teo EK, Tong M, Wong F, Hann HW, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology. 2005;129(2):528\u201336.","journal-title":"Gastroenterology."},{"issue":"26","key":"1126_CR33","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1056\/NEJMoa043470","volume":"352","author":"GK Lau","year":"2005","unstructured":"Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005;352(26):2682\u201395.","journal-title":"N Engl J Med."},{"key":"1126_CR34","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/hep.22658","volume":"49","author":"N Leung","year":"2009","unstructured":"Leung N, Peng CY, Hann HW, Sollano J, Lao-Tan J, Hsu CW, et al. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir. Hepatology. 2009;49:72\u20139.","journal-title":"Hepatology."},{"issue":"4","key":"1126_CR35","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1111\/jgh.12835","volume":"30","author":"X Liang","year":"2015","unstructured":"Liang X, Cheng J, Sun Y, Chen X, Li T, Wang H, et al. Randomized, three-arm study to optimize lamivudine efficacy in hepatitis B e antigen-positive chronic hepatitis B patients. Journal of gastroenterology and hepatology. 2015;30(4):748\u201355.","journal-title":"Journal of gastroenterology and hepatology."},{"key":"1126_CR36","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1007\/s11596-014-1312-2","volume":"34","author":"YH Liu","year":"2014","unstructured":"Liu YH, Wu T, Sun N, Wang GL, Yuan JZ, Dai YR, et al. Combination therapy with pegylated interferon alpha-2b and adefovir dipivoxil in HBeAg-positive chronic hepatitis B versus interferon alone: a prospective, randomized study. Journal of Huazhong University of Science and Technology Medical Sciences. 2014;34:542\u20137.","journal-title":"Journal of Huazhong University of Science and Technology Medical Sciences."},{"issue":"9","key":"1126_CR37","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1056\/NEJMoa020681","volume":"348","author":"P Marcellin","year":"2003","unstructured":"Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003;348(9):808\u201316.","journal-title":"N Engl J Med."},{"issue":"1","key":"1126_CR38","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1053\/j.gastro.2015.09.043","volume":"150","author":"P Marcellin","year":"2016","unstructured":"Marcellin P, Ahn SH, Ma X, Caruntu FA, Tak WY, Elkashab M, et al. Combination of tenofovir disoproxil fumarate and peginterferon \u03b1-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B. Gastroenterology. 2016;150(1):134\u201344. e10.","journal-title":"Gastroenterology"},{"issue":"31","key":"1126_CR39","doi-asserted-by":"publisher","first-page":"4264","DOI":"10.3748\/wjg.v13.i31.4264","volume":"13","author":"FY Ren","year":"2007","unstructured":"Ren FY, Piao DM, Piao XX. A one-year trial of entecavir treatment in patients with HBeAg-positive chronic hepatitis B. World J Gastroenterol. 2007;13(31):4264\u20137.","journal-title":"World J Gastroenterol."},{"issue":"3","key":"1126_CR40","doi-asserted-by":"publisher","first-page":"E161","DOI":"10.1111\/hepr.12743","volume":"47","author":"Tassanee Sriprayoon","year":"2016","unstructured":"Sriprayoon T, Mahidol C, Ungtrakul T, Chun-on P, Soonklang K, Pongpun W, et al. Efficacy and safety of entecavir versus tenofovir treatment in chronic hepatitis B patients: A randomized controlled trial. Hepatology Research. 2017;47(3):E161\u2013E168.","journal-title":"Hepatology Research"},{"issue":"5","key":"1126_CR41","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.jhep.2007.12.026","volume":"48","author":"JJY Sung","year":"2008","unstructured":"Sung JJY, Lai JY, Zeuzem S, Chow WC, Heathcote EJ, Perrillo RP, et al. Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. Journal of Hepatology. 2008;48(5):728\u201335.","journal-title":"Journal of Hepatology."},{"key":"1126_CR42","doi-asserted-by":"publisher","first-page":"755","DOI":"10.3851\/IMP2754","volume":"19","author":"K-C Tseng","year":"2014","unstructured":"Tseng K-C, Chen C-Y, Tsai H-W, Chang T-T, Chuang W-L, Hsu P-I, et al. Efficacy of entecavir in chronic hepatitis B patients with persistently normal alanine aminotransferase: randomized, double-blind, placebo-controlled study. Antivir Ther. 2014;19:755\u201364.","journal-title":"Antivir Ther."},{"issue":"12","key":"1126_CR43","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1093\/cid\/ciu702","volume":"59","author":"Q Xie","year":"2014","unstructured":"Xie Q, Zhou H, Bai X, Wu S, Chen J-J, Sheng J, et al. A randomized, open-label clinical study of combined pegylated Interferon Alfa-2a (40KD) and Entecavir treatment for Hepatitis B \u201ce\u201d Antigen\u2013Positive Chronic Hepatitis B. Clinical infectious diseases. 2014;59(12):1714\u201323.","journal-title":"Clinical infectious diseases."},{"issue":"31","key":"1126_CR44","doi-asserted-by":"publisher","first-page":"e4471","DOI":"10.1097\/MD.0000000000004471","volume":"95","author":"Ka Zhang","year":"2016","unstructured":"Zhang K, Cao H, Liang J, Shu X, Sun H, Li G, et al. CONSORT: Effects of adding adefovirdipivoxil to peginterferon alfa-2a at different time points on HBeAg-positivepatients: A prospective, randomized study. Medicine. 2016;95(31).","journal-title":"Medicine"},{"key":"1126_CR45","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1177\/135965350501000214","volume":"10","author":"H Bozkaya","year":"2005","unstructured":"Bozkaya H, Yurdaydin C, Idilman R, Tuzun A, Cinar K, Erkan O, et al. Lamivudine treatment in HBeAg-negative chronic hepatitis B patients with low level viraemia. Antiviral Therapy. 2005;10:319\u201325.","journal-title":"Antiviral Therapy."},{"issue":"3","key":"1126_CR46","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","volume":"1","author":"M Buti","year":"2016","unstructured":"Buti M, Gane E, Seto WK, Chan HL, Chuang W-L, Stepanova T, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. The Lancet Gastroenterology & Hepatology. 2016;1(3):196\u2013206.","journal-title":"The Lancet Gastroenterology & Hepatology."},{"key":"1126_CR47","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1177\/135965350701200308","volume":"12","author":"HLY Chan","year":"2007","unstructured":"Chan HLY, Wang H, Niu JQ, Chim AML, Sung JJY. Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial. Antiviral Therapy. 2007;12:345\u201353.","journal-title":"Antiviral Therapy."},{"issue":"9","key":"1126_CR48","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1056\/NEJMoa021812","volume":"348","author":"SJ Hadziyannis","year":"2003","unstructured":"Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med. 2003;348(9):800\u20137.","journal-title":"N Engl J Med."},{"issue":"8","key":"1126_CR49","doi-asserted-by":"publisher","first-page":"3020","DOI":"10.1128\/AAC.00088-07","volume":"51","author":"S Kaymakoglu","year":"2007","unstructured":"Kaymakoglu S, Oguz D, Gur G, Gurel S, Tankurt E, Ersoz G, et al. Pegylated interferon Alfa-2b monotherapy and pegylated interferon Alfa-2b plus lamivudine combination therapy for patients with hepatitis B virus E antigen-negative chronic hepatitis B. Antimicrob Agents Chemother. 2007;51(8):3020\u20132.","journal-title":"Antimicrob Agents Chemother."},{"issue":"10","key":"1126_CR50","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1056\/NEJMoa051287","volume":"354","author":"C-L Lai","year":"2006","unstructured":"Lai C-L, Shouval D, Lok AS, Chang T-T, Cheinquer H, Goodman Z, et al. Entecavir versus Lamivudine for patients with HBeAg-negative chronic hepatitis B. New England Journal of Medicine. 2006;354(10):1011\u201320.","journal-title":"New England Journal of Medicine."},{"key":"1126_CR51","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1136\/gutjnl-2011-301430","volume":"62","author":"P Lampertico","year":"2013","unstructured":"Lampertico P, Vigano M, Di Costanzo GG, Sagnelli E, Fasano M, Di Marco V, et al. Randomised study comparing 48 and 96 weeks peginterferon alpha-2a therapy in genotype D HBeAg-negative chronic hepatitis B. Gut. 2013;62:290\u20138.","journal-title":"Gut."},{"issue":"4","key":"1126_CR52","doi-asserted-by":"publisher","first-page":"331","DOI":"10.3350\/cmh.2016.0040","volume":"23","author":"KS Lee","year":"2017","unstructured":"Lee KS, Kweon Y-O, Um S-H, Kim B-H, Lim YS, Paik SW, et al. Efficacy and safety of entecavir versus lamivudine over 5 years of treatment: a randomized controlled trial in Korean patients with hepatitis B e antigen-negative chronic hepatitis B. Clinical and molecular hepatology. 2017;23(4):331.","journal-title":"Clinical and molecular hepatology."},{"issue":"12","key":"1126_CR53","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1056\/NEJMoa040431","volume":"351","author":"P Marcellin","year":"2004","unstructured":"Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2004;351(12):1206\u201317.","journal-title":"N Engl J Med."},{"key":"1126_CR54","first-page":"CR56","volume":"15","author":"VP Papadopoulos","year":"2009","unstructured":"Papadopoulos VP, Chrysagis DN, Protopapas AN, Goulis IG, Dimitriadis GT, Mimidis KP. Peginterferon alfa-2b as monotherapy or in combination with lamivudine in patients with hbeag-negative chronic hepatitis b: a randomised study. Medical Science Monitor. 2009;15:CR56\u201361.","journal-title":"Medical Science Monitor."},{"issue":"8","key":"1126_CR55","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.3851\/IMP1466","volume":"14","author":"P Piccolo","year":"2009","unstructured":"Piccolo P, Lenci I, Demelia L, Bandiera F, Piras MR, Antonucci G, et al. A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B. Antivir Ther. 2009;14(8):1165\u201374.","journal-title":"Antivir Ther."},{"issue":"6","key":"1126_CR56","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1111\/jvh.12467","volume":"23","author":"P Tangkijvanich","year":"2016","unstructured":"Tangkijvanich P, Chittmittraprap S, Poovorawan K, Limothai U, Khlaiphuengsin A, Chuaypen N, et al. A randomized clinical trial of peginterferon alpha-2b with or without entecavir in patients with HBeAg-negative chronic hepatitis B: Role of host and viral factors associated with treatment response. Journal of viral hepatitis. 2016;23(6):427\u201338.","journal-title":"Journal of viral hepatitis."},{"key":"1126_CR57","first-page":"889","volume":"29","author":"NC Tassopoulos","year":"1999","unstructured":"Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin RD, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative\/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology. 1999;29:889\u201396.","journal-title":"Lamivudine Precore Mutant Study Group. Hepatology."},{"issue":"2","key":"1126_CR58","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/jvh.12313","volume":"22","author":"J Hou","year":"2015","unstructured":"Hou J, Gao Z, Xie Q, Zhang J, Sheng J, Cheng J, et al. Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trial. Journal of viral hepatitis. 2015;22(2):85\u201393.","journal-title":"Journal of viral hepatitis."},{"key":"1126_CR59","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s12072-013-9488-2","volume":"8","author":"JD Jia","year":"2014","unstructured":"Jia JD, Hou JL, Yin YK, Tan DM, Xu DZ, Niu JQ, et al. Two-year results of a randomized, phase III comparative trial of telbivudine versus lamivudine in Chinese patients. Hepatology International. 2014;8:72\u201382.","journal-title":"Hepatology International."},{"key":"1126_CR60","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1053\/j.gastro.2008.10.026","volume":"136","author":"YF Liaw","year":"2009","unstructured":"Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, et al. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology. 2009;136:486\u201395.","journal-title":"Gastroenterology."},{"key":"1126_CR61","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1053\/j.gastro.2012.05.037","volume":"143","author":"AS Lok","year":"2012","unstructured":"Lok AS, Trinh H, Carosi G, Akarca US, Gadano A, Habersetzer F, et al. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-nave patients with chronic hepatitis B. Gastroenterology. 2012;143:619\u201328.e1.","journal-title":"Gastroenterology"},{"issue":"23","key":"1126_CR62","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1056\/NEJMoa0802878","volume":"359","author":"P Marcellin","year":"2008","unstructured":"Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, et al. Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B. N Engl J Med. 2008;359(23):2442\u201355.","journal-title":"N Engl J Med."},{"key":"1126_CR63","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s12072-007-9009-2","volume":"1","author":"GB Yao","year":"2007","unstructured":"Yao GB, Chen CW, Lu WL, Ren H, Tan DM, Wang YM, et al. Efficacy and safety of entecavir compared to lamivudine in nucleoside-naive patients with chronic hepatitis B: a randomized double-blind trial in China. Hepatology International. 2007;1:365\u201372.","journal-title":"Hepatology International."},{"issue":"1","key":"1126_CR64","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13643-017-0473-z","volume":"6","author":"L Mbuagbaw","year":"2017","unstructured":"Mbuagbaw L, Rochwerg B, Jaeschke R, Heels-Andsell D, Alhazzani W, Thabane L, et al. Approaches to interpreting and choosing the best treatments in network meta-analyses. Systematic Reviews. 2017;6(1):79.","journal-title":"Systematic Reviews."},{"issue":"Suppl 2","key":"1126_CR65","first-page":"A97","volume":"67","author":"HL-Y Chan","year":"2018","unstructured":"Chan HL-Y, Buti M, Flisiak R, Ryder S, Streinu-Cercel A, Flaherty JF, et al. IDDF2018-ABS-0107\u00a0Efficacy and safety of TENOFOVIR ALAFENAMIDE (TAF) at 96 weeks in chronic HBV (CHB) patients with risk factors for use of TENOFOVIR DISOPROXIL FUMARATE (TDF). Gut. 2018;67(Suppl 2):A97\u2013A.","journal-title":"Gut"},{"issue":"4","key":"1126_CR66","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.jhep.2017.11.039","volume":"68","author":"K Agarwal","year":"2018","unstructured":"Agarwal K, Brunetto M, Seto WK, Lim Y-S, Fung S, Marcellin P, et al. 96&#x202f;weeks treatment of tenofovir alafenamide <em>vs<\/em>. tenofovir disoproxil fumarate for hepatitis B virus infection. Journal of Hepatology. 2018;68(4):672\u201381.","journal-title":"Journal of Hepatology."},{"key":"1126_CR67","doi-asserted-by":"publisher","first-page":"3197","DOI":"10.2147\/DDDT.S126742","volume":"11","author":"E Ogawa","year":"2017","unstructured":"Ogawa E, Furusyo N, Nguyen MH. Tenofovir alafenamide in the treatment of chronic hepatitis B: design, development, and place in therapy. Drug Design, Development and Therapy. 2017;11:3197\u2013204.","journal-title":"Drug Design, Development and Therapy."},{"issue":"4","key":"1126_CR68","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1089\/aid.2017.0203","volume":"34","author":"E DeJesus","year":"2018","unstructured":"DeJesus E, Haas B, Segal-Maurer S, Ramgopal MN, Mills A, Margot N, et al. Superior efficacy and improved renal and bone safety after switching from a tenofovir disoproxil fumarate- to a tenofovir alafenamide-based regimen through 96 weeks of treatment. AIDS Research and Human Retroviruses. 2018;34(4):337\u201342.","journal-title":"AIDS Research and Human Retroviruses."},{"key":"1126_CR69","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.antiviral.2015.11.009","volume":"125","author":"AS Ray","year":"2016","unstructured":"Ray AS, Fordyce MW, Hitchcock MJM. Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus. Antiviral Research. 2016;125:63\u201370.","journal-title":"Antiviral Research."},{"key":"1126_CR70","doi-asserted-by":"publisher","first-page":"469","DOI":"10.3851\/IMP1772","volume":"16","author":"YE Chon","year":"2011","unstructured":"Chon YE, Kim SU, Lee CK, Heo J, Kim JK, Yoon KT, et al. Partial virological response to entecavir in treatment-naive patients with chronic hepatitis B. Antiviral Therapy. 2011;16:469\u201377.","journal-title":"Antiviral Therapy."},{"key":"1126_CR71","first-page":"10010","volume-title":"Cost-effectiveness analysis of first-line administration of tenofoviR alafenamide (TAF), a novel nucleotide Reverse transcriptase inhibitor (NRTI), for the management of chronic hepatitis B (CHB) In the United States (US). Value in health","author":"G Dusheiko","year":"2017","unstructured":"Dusheiko G, Lim J, Liou I, Tafazzoli A, Deniz B, Thibault S-LC, et al. Cost-effectiveness analysis of first-line administration of tenofoviR alafenamide (TAF), a novel nucleotide Reverse transcriptase inhibitor (NRTI), for the management of chronic hepatitis B (CHB) In the United States (US). Value in health. New York: Elsevier Science INC; 2017. p. 10010\u20131710."},{"issue":"1","key":"1126_CR72","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/hep.28156","volume":"63","author":"NA Terrault","year":"2016","unstructured":"Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63(1):261\u201383.","journal-title":"Hepatology."},{"key":"1126_CR73","unstructured":"Organization WH. Guidelines for the Prevention Care and Treatment of Persons with Chronic Hepatitis B Infection: Mar-15: World Health Organization; 2015."},{"key":"1126_CR74","volume-title":"Class Update: Antivirals for Hepatitis B","author":"M Smith","year":"2012","unstructured":"Smith M. Class Update: Antivirals for Hepatitis B; 2012."},{"issue":"5","key":"1126_CR75","doi-asserted-by":"publisher","first-page":"227","DOI":"10.4254\/wjh.v9.i5.227","volume":"9","author":"B Kayaaslan","year":"2017","unstructured":"Kayaaslan B, Guner R. Adverse effects of oral antiviral therapy in chronic hepatitis B. World Journal of Hepatology. 2017;9(5):227\u201341.","journal-title":"World Journal of Hepatology."},{"issue":"7","key":"1126_CR76","doi-asserted-by":"publisher","first-page":"159","DOI":"10.21037\/atm.2017.03.69","volume":"5","author":"ASJ Woo","year":"2017","unstructured":"Woo ASJ, Kwok R, Ahmed T. Alpha-interferon treatment in hepatitis B. Annals of Translational Medicine. 2017;5(7):159.","journal-title":"Annals of Translational Medicine."},{"issue":"5","key":"1126_CR77","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1111\/j.1365-2036.2010.04555.x","volume":"33","author":"V Rijckborst","year":"2011","unstructured":"Rijckborst V, Sonneveld MJ, Janssen H. chronic hepatitis B\u2013anti-viral or immunomodulatory therapy? Alimentary pharmacology & therapeutics. 2011;33(5):501\u201313.","journal-title":"Alimentary pharmacology & therapeutics."},{"issue":"2","key":"1126_CR78","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.bpg.2009.10.012","volume":"24","author":"F Negro","year":"2010","unstructured":"Negro F. Adverse effects of drugs in the treatment of viral hepatitis. Best Practice & Research Clinical Gastroenterology. 2010;24(2):183\u201392.","journal-title":"Best Practice & Research Clinical Gastroenterology."},{"issue":"S5","key":"1126_CR79","doi-asserted-by":"publisher","first-page":"S112","DOI":"10.1002\/hep.22920","volume":"49","author":"JL Dienstag","year":"2009","unstructured":"Dienstag JL. Benefits and risks of nucleoside analog therapy for hepatitis B. Hepatology. 2009;49(S5):S112\u2013S21.","journal-title":"Hepatology."},{"issue":"6","key":"1126_CR80","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1053\/j.gastro.2009.08.061","volume":"137","author":"EH Buster","year":"2009","unstructured":"Buster EH, Hansen BE, Lau GK, Piratvisuth T, Zeuzem S, Steyerberg EW, et al. Factors that predict response of patients with hepatitis B e antigen\u2013Positive chronic hepatitis B to peginterferon-alfa. Gastroenterology. 2009;137(6):2002\u20139.","journal-title":"Gastroenterology."},{"issue":"1","key":"1126_CR81","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/cld.152","volume":"2","author":"P Arends","year":"2013","unstructured":"Arends P, Sonneveld MJ, Janssen HL. Hepatitis B virus treatment: which patients should be treated with interferon? Clinical Liver Disease. 2013;2(1):18\u201320.","journal-title":"Clinical Liver Disease."},{"issue":"5","key":"1126_CR82","doi-asserted-by":"publisher","first-page":"590","DOI":"10.5009\/gnl16215","volume":"11","author":"T-H Su","year":"2017","unstructured":"Su T-H, Liu C-J. Combination therapy for chronic hepatitis B: current updates and perspectives. Gut and liver. 2017;11(5):590.","journal-title":"Gut and liver."},{"issue":"1","key":"1126_CR83","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.jhep.2014.08.056","volume":"62","author":"S Chen","year":"2015","unstructured":"Chen S, Zhang W. HBeAg-positive chronic hepatitis B patients with prior long-time exposure to nucleos (t) ide analogues:\u201cSwitch-to\u201d or \u201cadd-on\u201d PegIFN alfa, that is the question. Journal of hepatology. 2015;62(1):239.","journal-title":"Journal of hepatology."},{"issue":"4","key":"1126_CR84","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok AS, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560\u201399.","journal-title":"Hepatology."},{"issue":"8","key":"1126_CR85","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1097\/MEG.0000000000000376","volume":"27","author":"L Govan","year":"2015","unstructured":"Govan L, Wu O, Xin Y, Hutchinson SJ, Hawkins N. Comparative effectiveness of antiviral treatment for hepatitis B: A systematic review and Bayesian network meta-analysis. European Journal of Gastroenterology and Hepatology. 2015;27(8):882\u201394.","journal-title":"European Journal of Gastroenterology and Hepatology."},{"issue":"4","key":"1126_CR86","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s12325-016-0305-x","volume":"33","author":"X Liang","year":"2016","unstructured":"Liang X, Fan R, Sun J, Shaikh J, Taneja A, Gupta S, et al. Effect of telbivudine versus other nucleos (t) ide analogs on HBeAg seroconversion and other outcomes in patients with chronic hepatitis B: a network meta-analysis. Advances in therapy. 2016;33(4):519\u201331.","journal-title":"Advances in therapy."},{"issue":"1","key":"1126_CR87","doi-asserted-by":"publisher","first-page":"e0169444","DOI":"10.1371\/journal.pone.0169444","volume":"12","author":"T Xing","year":"2017","unstructured":"Xing T, Xu H, Cao L, Ye M. HBeAg seroconversion in HBeAg-positive chronic hepatitis B Patients receiving long-term nucleos(t)ide analog treatment: a systematic review and network meta-analysis. PLOS ONE. 2017;12(1):e0169444.","journal-title":"PLOS ONE."},{"issue":"5","key":"1126_CR88","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s12072-016-9737-2","volume":"10","author":"F Zoulim","year":"2016","unstructured":"Zoulim F, Bia\u0142kowska-Warzecha J, Diculescu MM, Goldis AE, Heyne R, Mach T, et al. Entecavir plus tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos (t) ide treatment failure. Hepatology international. 2016;10(5):779\u201388.","journal-title":"Hepatology international."},{"issue":"2","key":"1126_CR89","doi-asserted-by":"publisher","first-page":"189","DOI":"10.5009\/gnl15562","volume":"11","author":"Y-S Lim","year":"2017","unstructured":"Lim Y-S. Management of Antiviral Resistance in Chronic Hepatitis B. Gut and Liver. 2017;11(2):189\u201395.","journal-title":"Gut and Liver."},{"issue":"6","key":"1126_CR90","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.jfma.2013.02.001","volume":"112","author":"C-L Lin","year":"2013","unstructured":"Lin C-L, Kao J-H. Hepatitis B viral factors and treatment responses in chronic hepatitis B. Journal of the Formosan Medical Association. 2013;112(6):302\u201311.","journal-title":"Journal of the Formosan Medical Association."},{"key":"1126_CR91","doi-asserted-by":"publisher","first-page":"29605","DOI":"10.1038\/srep29605","volume":"6","author":"Y-C Wang","year":"2016","unstructured":"Wang Y-C, Yang S-S, Su C-W, Wang Y-J, Lee K-C, Huo T-I, et al. Predictors of response to pegylated interferon in chronic hepatitis B: a real-world hospital-based analysis. Scientific Reports. 2016;6:29605.","journal-title":"Scientific Reports."},{"issue":"4","key":"1126_CR92","doi-asserted-by":"publisher","first-page":"636","DOI":"10.3904\/kjim.2016.096","volume":"32","author":"J-Y Cho","year":"2017","unstructured":"Cho J-Y, Sohn W, Sinn D-H, Gwak G-Y, Paik Y-H, Choi MS, et al. Long-term real-world entecavir therapy in treatment-na\u00efve hepatitis B patients: base-line hepatitis B virus DNA and hepatitis B surface antigen levels predict virologic response. The Korean journal of internal medicine. 2017;32(4):636.","journal-title":"The Korean journal of internal medicine."},{"issue":"6","key":"1126_CR93","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/j.jhep.2013.07.017","volume":"59","author":"MR Brunetto","year":"2013","unstructured":"Brunetto MR, Marcellin P, Cherubini B, Yurdaydin C, Farci P, Hadziyannis SJ, et al. Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: on-treatment kinetics of HBsAg serum levels vary by HBV genotype. Journal of hepatology. 2013;59(6):1153\u20139.","journal-title":"Journal of hepatology."},{"issue":"1-2","key":"1126_CR94","first-page":"43","volume":"52","author":"M Enomoto","year":"2006","unstructured":"Enomoto M, Tamori A, Nishiguchi S. Hepatitis B virus genotypes and response to antiviral therapy. Clinical laboratory. 2006;52(1-2):43\u20137.","journal-title":"Clinical laboratory."},{"issue":"1","key":"1126_CR95","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/1741-7015-9-79","volume":"9","author":"T Li","year":"2011","unstructured":"Li T, Puhan MA, Vedula SS, Singh S, Dickersin K. Network meta-analysis-highly attractive but more methodological research is needed. BMC medicine. 2011;9(1):79.","journal-title":"BMC medicine."},{"issue":"1","key":"1126_CR96","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/2046-4053-3-21","volume":"3","author":"S Mealing","year":"2014","unstructured":"Mealing S, Ghement I, Hawkins N, Scott DA, Lescrauwaet B, Watt M, et al. The importance of baseline viral load when assessing relative efficacy in treatment-na\u00efve HBeAg-positive chronic hepatitis B: a systematic review and network meta-analysis. Systematic reviews. 2014;3(1):21.","journal-title":"Systematic reviews."},{"issue":"7","key":"1126_CR97","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1080\/13543784.2017.1333105","volume":"26","author":"V Soriano","year":"2017","unstructured":"Soriano V, Barreiro P, Benitez L, Pe\u00f1a JM, de Mendoza C. New antivirals for the treatment of chronic hepatitis B. Expert opinion on investigational drugs. 2017;26(7):843\u201351.","journal-title":"Expert opinion on investigational drugs."},{"issue":"3","key":"1126_CR98","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.bpg.2017.04.007","volume":"31","author":"JS Emery","year":"2017","unstructured":"Emery JS, Feld JJ. Treatment of hepatitis B virus with combination therapy now and in the future. Best Practice & Research Clinical Gastroenterology. 2017;31(3):347\u201355.","journal-title":"Best Practice & Research Clinical Gastroenterology."},{"issue":"S1","key":"1126_CR99","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/liv.13304","volume":"37","author":"EJ Gane","year":"2017","unstructured":"Gane EJ. Future anti-HBV strategies. Liver International. 2017;37(S1):40\u20134.","journal-title":"Liver International."},{"issue":"1","key":"1126_CR100","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12916-017-0820-x","volume":"15","author":"T-C Tseng","year":"2017","unstructured":"Tseng T-C, Kao J-H. Elimination of hepatitis B: is it a mission possible? BMC medicine. 2017;15(1):53.","journal-title":"BMC medicine."}],"container-title":["Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-019-1126-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13643-019-1126-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-019-1126-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T05:08:53Z","timestamp":1721624933000},"score":1,"resource":{"primary":{"URL":"https:\/\/systematicreviewsjournal.biomedcentral.com\/articles\/10.1186\/s13643-019-1126-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,19]]},"references-count":100,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1126"],"URL":"https:\/\/doi.org\/10.1186\/s13643-019-1126-1","relation":{},"ISSN":["2046-4053"],"issn-type":[{"value":"2046-4053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,19]]},"assertion":[{"value":"14 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"William Wong and Murray Krahn have received research support from the Canadian Liver Foundation. Harry L. A. Janssen received grants from AbbVie, Bristol Myers Squibb, Gilead Sciences, Innogenetics, Janssen, Medimmune, Medtronic, Merck, and Roche and is consultant for AbbVie, Benitec, Bristol Myers Squibb, Gilead Sciences, Janssen, Medimmune, Merck, Roche and Arbutus. None of the other co-authors has any conflict of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"207"}}